Online citations, reference lists, and bibliographies.

The Anti-cancer Drug Lenalidomide Inhibits Angiogenesis And Metastasis Via Multiple Inhibitory Effects On Endothelial Cell Function In Normoxic And Hypoxic Conditions.

Ling Lu, Faribourz Payvandi, Lei Wu, Li Zhang, Robert J. Hariri, Ho Kai Man, Roger Shen-Chu Chen, George W. Muller, Christopher C. W. Hughes, David I. Stirling, Peter H. Schafer, Justin Blake Bartlett
Published 2009 · Biology, Medicine
Cite This
Download PDF
Analyze on Scholarcy
Lenalidomide (Revlimid) is approved for the treatment of transfusion-dependent patients with anemia due to low- or intermediate-1-risk Myelodysplastic Syndromes (MDS) associated with a del 5q cytogenetic abnormality with or without additional cytogenetic abnormalities, and in combination with dexamethasone for the treatment of multiple myeloma patients who have received at least one prior therapy. Previous reports suggest that lenalidomide is anti-angiogenic and this property appears to be related to efficacy in patients with MDS. We have investigated the effect of lenalidomide on the formation of microvessels in a novel in vitro angiogenesis assay utilizing human umbilical arterial rings and in a capillary-like cord formation assay using cultured primary endothelial cells. We found that lenalidomide consistently inhibits both sprout formation by arterial rings and cord formation by endothelial cells in a dose-dependent manner. We also found an inhibitory effect of lenalidomide on the associations between cadherin 5, beta-catenin and CD31, adherens junction proteins whose interaction is critical for endothelial cell cord formation. Furthermore, lenalidomide inhibited VEGF-induced PI3K-Akt pathway signaling, which is known to regulate adherens junction formation. We also found a strong inhibitory effect of lenalidomide on hypoxia-induced endothelial cell formation of cords and HIF-1 alpha expression, the main mediator of hypoxia-mediated effects and a key driver of angiogenesis and metastasis. Anti-metastatic activity of lenalidomide in vivo was confirmed in the B16-F10 mouse melanoma model by a >40% reduction in melanoma lung colony counts versus untreated mice. Our results suggest that inhibitory effects on microvessel formation, in particular adherens junction formation and inhibition of hypoxia-induced processes support a potential anti-angiogenic and anti-metastatic mechanism for this clinically active drug.
This paper references
Hypoxia signalling in cancer and approaches to enforce tumour regression
Jacques Pouyssegur (2006)
Measurements of endothelial cell-to-cell and cell-to-substrate gaps and micromechanical properties of endothelial cells during monocyte adhesion
Noriyuki Kataoka (2002)
Anti-Angiogenic In Vivo Effect of Lenalidomide (CC-5013) in Myelodysplastic Syndrome with del(5q) Chromosome Abnormality and Its Relation to the Course of Disease.
Guntram Büsche (2005)
Role of Akt Signaling in Vascular Homeostasis and Angiogenesis
Ichiro Shiojima (2002)
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma.
Paul G Richardson (2006)
Thalidomide is an inhibitor of angiogenesis.
Robert J D'Amato (1994)
Orally administered lenalidomide (CC-5013) is anti-angiogenic in vivo and inhibits endothelial cell migration and Akt phosphorylation in vitro.
Keith Dredge (2005)
Clinical translation of angiogenesis inhibitors
Robert S. Kerbel (2002)
Novel thalidomide analogues display anti-angiogenic activity independently of immunomodulatory effects
Keith Dredge (2002)
Current methods for assaying angiogenesis in vitro and in vivo.
Carolyn A. Staton (2004)
Endothelial cell tube formation depends on cadherin 5 and CD31 interactions with filamentous actin.
Takeshi Matsumura (1997)
Hypoxia — a key regulatory factor in tumour growth
Adrian L. Harris (2002)
Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion.
Alan F List (2006)
Preconditioning of the tumor vasculature and tumor cells by intermittent hypoxia: implications for anticancer therapies.
Philippe Martinive (2006)
Is angiogenesis inhibition the Holy Grail of cancer therapy?
T Boehm-Viswanathan (2000)
Inhibition of vascular endothelial growth factor-induced angiogenesis by resveratrol through interruption of Src-dependent vascular endothelial cadherin tyrosine phosphorylation.
Ming-Tsan Lin (2003)
Akt and Hypoxia-Inducible Factor-1 Independently Enhance Tumor Growth and Angiogenesis
Andrew M Arsham (2004)
The evolution of thalidomide and its IMiD derivatives as anticancer agents
J. Blake Bartlett (2004)
Hypoxic induction of an HIF-1alpha-dependent bFGF autocrine loop drives angiogenesis in human endothelial cells.
Maura Calvani (2006)
Angiogenesis in cancer and other diseases
Peter Carmeliet (2000)
Regulation of Hypoxia-inducible Factor-1α Protein Level during Hypoxic Conditions by the Phosphatidylinositol 3-Kinase/Akt/Glycogen Synthase Kinase 3β Pathway in HepG2 Cells*
Denis Mottet (2003)
Antiangiogenic therapy and tumor progression.
Mikhail V. Blagosklonny (2004)
Hypoxia-Inducible Factor-1α Is a Key Regulator of Metastasis in a Transgenic Model of Cancer Initiation and Progression
Debbie Liao (2007)
Activation of the Phosphatidylinositol 3-Kinase/Protein Kinase Akt Pathway Mediates Nitric Oxide-Induced Endothelial Cell Migration and Angiogenesis
Koh Kawasaki (2003)
The Hallmarks of Cancer
Douglas Hanahan (2000)

This paper is referenced by
alidomide in Nonmetastatic Biochemically Relapsed state Cancer: Results of a Phase I/II
Len Pro Dou (2010)
Effect of induction therapy with lenalidomide, doxorubicin and dexamethasone on bone remodeling and angiogenesis in newly diagnosed multiple myeloma.
Evangelos Terpos (2019)
HIF-1α inhibition blocks the cross talk between multiple myeloma plasma cells and tumor microenvironment.
Enrica Borsi (2014)
The European medicines agency review of pomalidomide in combination with low-dose dexamethasone for the treatment of adult patients with multiple myeloma: summary of the scientific assessment of the committee for medicinal products for human use.
Zahra Hanaizi (2015)
Angiogenesis and Progression in Human Melanoma
Roberto Ria (2010)
Lenalidomide normalizes tumor vessels in colorectal cancer improving chemotherapy activity
Valeria Leuci (2016)
Immunomodulatory Effects of Small-Molecule Compounds: Impact on Hematologic Malignancies
Noriyoshi Iriyama (2017)
Targeting C-Met/VEGF in Castration Resistant Prostate Cancer
Petros D. Grivas (2014)
Lenalidomide mode of action: linking bench and clinical findings.
Faith Davies (2010)
Inhibition of HIF1α-Dependent Upregulation of Phospho-l-Plastin Resensitizes Multiple Myeloma Cells to Frontline Therapy
Manon Bosseler (2018)
Elotuzumab enhances natural killer cell activation and myeloma cell killing through interleukin-2 and TNF-α pathways
Balaji Balasa (2014)
Lenalidomide monotherapy in chemotherapy-naive, castration-resistant prostate cancer patients: final results of a phase II study.
Chadi Nabhan (2014)
Aspirin inhibits proliferation and induces apoptosis of multiple myeloma cells through regulation of Bcl-2 and Bax and suppression of VEGF.
Jiang-Hua Ding (2014)
Pomalidomide is nonteratogenic in chicken and zebrafish embryos and nonneurotoxic in vitro
Chris Mahony (2013)
Immunomodulatory drugs improve the immune environment for dendritic cell-based immunotherapy in multiple myeloma patients after autologous stem cell transplantation
Brenda De Keersmaecker (2014)
Lenalidomide: deciphering mechanisms of action in myeloma, myelodysplastic syndrome and beyond.
Andrew A Guirguis (2015)
Endothelium-mediated survival of leukemic cells and angiogenesis-related factors are affected by lenalidomide treatment in chronic lymphocytic leukemia.
Rossana Maffei (2014)
Reply to D’Amato et al. and Zeldis et al.: Screening of thalidomide derivatives in chicken and zebrafish embryos
Neil Vargesson (2013)
Mechanism of immunomodulatory drugs' action in the treatment of multiple myeloma.
Xiubao Chang (2014)
A critical evaluation of in vitro cell culture models for high-throughput drug screening and toxicity.
Anna I Astashkina (2012)
Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide
Antonia Lopez-Girona (2012)
Bone marrow vascular niche and the control of angiogenesis in multiple myeloma.
Domenico Ribatti (2014)
Modeling and Simulation to Probe the Pharmacokinetic Disposition of Pomalidomide Rand S-Enantiomers
Yan Li (2014)
The safety of pomalidomide for the treatment of multiple myeloma
John Rhys Jones (2016)
A perforated microhole-based microfluidic device for improving sprouting angiogenesis in vitro
Sijia Chen (2017)
Lenalidomide use in myelodysplastic syndromes: Insights into the biologic mechanisms and clinical applications.
Maximilian Stahl (2017)
Treatment of Lymphoid and Myeloid Malignancies by Immunomodulatory Drugs.
Ota Fuchs (2019)
Lenalidomide improves the therapeutic effect of an interferon-α-dendritic cell-based lymphoma vaccine
Caterina Lapenta (2019)
Pomalidomide: evaluation of cytochrome P450 and transporter-mediated drug-drug interaction potential in vitro and in healthy subjects.
Claudia Kasserra (2015)
Ľubica Roziaková (2014)
Role of Angiogenesis and Microenvironment in Melanoma Progression
Roberto Ria (2011)
The Effect of Small Organic Compounds on Triple Negative Breast Cancer Cells
John D. O'Brien (2012)
See more
Semantic Scholar Logo Some data provided by SemanticScholar